Jazz Pharmaceuticals, a specialty pharmaceutical company, has announced the issuance of new formulation patent for Xyrem (sodium oxybate) oral solution.
Xyrem (sodium oxybate) oral solution is the FDA approved product for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy.
The new patent entitled Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy will expire in December 2019.
Jazz Pharmaceuticals chairman and chief executive officer Bruce Cozadd said, "Continually enhancing the patient and provider experience with Xyrem is an important strategic priority for our company, and our intellectual property related to Xyrem has been integral to ensuring the safe and effective use of sodium oxybate for the past 10 years."
In addition to the new patent, nine other US patents have been issued related to Xyrem's stable and microbially resistant formulation, its manufacturing process and its method of use, including its restricted distribution system, according to the company.
